NCT00737867

Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer

Vinorelbine Plus Gemcitabine (VG) Versus Vinorelbine Plus Carboplatin (VC) in Advanced Non-small Cell Lung Cancer. An Open Randomized Multicenter Phase III Trial From Norwegian Lung Cancer Study Group (NLCG)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 444 (estimated)
• Sponsor: The Norwegian Lung Cancer Study Group · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to explore if the combination of vinorelbine and gemcitabine is better than vinorelbine and carboplatin in the treatment of advanced non-small cell lung cancer, in terms of survival, quality of life and need for palliative radiotherapy.

Conditions

• Advanced Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Vinorelbine	Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
DRUG	Gemcitabine	Day 1: Gemcitabine infusion 1000 mg/m2 Day 8: Gemcitabine infusion 1000 mg/m2
DRUG	Vinorelbine	Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
DRUG	Carboplatin	Day 1: Carboplatin infusion AUC = 5 (Calvert's formula)

Timeline

• Start date: 2007-09-01
• Primary completion: 2011-02-01
• Completion: 2011-02-01
• First posted: 2008-08-20
• Last updated: 2011-04-04

Locations

4 sites across 1 country: Norway